Evidence map›Paper›PMID 29854934›Full record

ArticleAlzheimer's & dementia (New York, N. Y.)2015

Alzheimer's disease progression model using disability assessment for dementia scores from bapineuzumab trials.

Steven X Xu, Mahesh N Samtani, Alberto Russu, Omoniyi J Adedokun, Ming Lu, Kaori Ito, Brian Corrigan, Sangeeta Raje, H Robert Brashear, Scot Styren and 1 more

2 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia (New York, N. Y.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00574132 phase3completednot on this map

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Non- Carriers.

TypeinterventionalSponsorJANSSEN Alzheimer Immunotherapy Research & Development, LLCRan2007 to 2012Enrolled1,331ConditionsAlzheimer's DiseaseArmsBapineuzumab 0.5 mg/kg, Placebo Control, Bapineuzumab 1.0 m/kg
NCT00575055 phase3completednot on this map

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Carriers.

TypeinterventionalSponsorJANSSEN Alzheimer Immunotherapy Research & Development, LLCRan2007 to 2012Enrolled1,121ConditionsAlzheimer's DiseaseArmsBapineuzumab 0.5 mg/kg, Placebo Control, Bapineuzumab 1.0 m/kg
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Steven X XuJanssen Research & Development, LLC, Raritan, NJ, USA.
Mahesh N SamtaniJanssen Research & Development, LLC, Raritan, NJ, USA.
Alberto RussuJanssen Research & Development, Beerse, Belgium.
Omoniyi J AdedokunJanssen Research & Development LLC, Spring House, PA, USA.
Ming LuJanssen Research & Development LLC, Spring House, PA, USA.
Kaori ItoPfizer Inc, Groton, CT, USA.
Brian CorriganPfizer Inc, Groton, CT, USA.
Sangeeta RajePfizer Inc, Groton, CT, USA.
H Robert BrashearJanssen Alzheimer Immunotherapy Research & Development, LLC, South San Francisco, CA, USA.
Scot StyrenPfizer Inc, Groton, CT, USA.
Chuanpu HuJanssen Research & Development LLC, Spring House, PA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveDisability assessment for dementia (DAD) measurements from two phase-3 studies of bapineuzumab in

methodsWe evaluated longitudinal changes in DAD scores, baseline factors affecting disease progression, and bapineuzumab effect on disease progression.

resultsA beta regression model best described DAD disease progression. The estimated treatment effect of bapineuzumab was not significant, consistent with lack of clinical efficacy observed in the primary analysis. The model suggested that progression of DAD tended to decrease with increase in bapineuzumab exposure. The exposure-response relationship was similar regardless of

conclusionsThe beta regression model is a sensible modeling approach to characterize functional decline in AD patients. This analysis suggested a possible effect of bapineuzumab exposure on DAD progression. Further evaluation may be warranted in future studies.

trial registrationClinicalTrials.gov identifier: NCT00575055 and NCT00574132.

Indexed as

Alzheimer's diseaseBapineuzumabDisability assessment for dementiaDisease progression model

Identifiers

PMID29854934
PMCPMC5975025

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.